SEC Form 4 · accession 0001104659-18-000371
Axovant Sciences Ltd. · AXON
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David Hung
Officer — Principal Executive Officer · Director
Period of report
Dec 29, 2017
Accepted (ET)
Jan 3, 2018 · 8:48 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001636050
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $5.27 | Dec 29, 2017 | M | 2,000,000 | A | — | Dec 29, 2027 | Common Stock | 2,000,000 | 2,000,000 | D |
Explanation of responses
- F1This option is immediately exercisable, subject to a repurchase right in favor of the Issuer that lapses as the option vests. 20% of the common shares underlying the option vest on December 29, 2018, and the balance of the shares vest in a series of 16 successive equal quarterly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date, but only if the 30-consecutive day volume-weighted average closing price of the Issuer's common shares equals or exceeds $7.91 at any point during the 10-year term of the option.